Association of proton pump inhibitor use with the development of febrile neutropenia in lymphoma patients. Issue 5 (4th May 2021)

• Record Type: Journal Article
• Authors: Hazzan, Rawi; Darawsha, Usama; Neeman, Ziv; Aviv, Ariel
• Is Part Of: Expert review of hematology. Volume 14:Issue 5(2021)
• Page Start: 503
• Page End: 507
• Publication Date: 2021-05-04
• Subjects: Infectious diseases -- immunology -- lymphoma -- proton pump inhibitors -- febrile neutropenia -- clinical trials; Hematology -- Periodicals; 616.15005
• DOI: 10.1080/17474086.2021.1920011
• Languages: English
• ISSNs: 1747-4086

Abstract

ABSTRACT: Background : Proton pump inhibitors (PPIs), although relatively safe drugs for reduction of gastric acid production, continue to raise concerns (i.e. potential infectious complications, electrolyte disturbances). PPIs are frequently administered to hemato-oncological patients receiving chemotherapy. The study main objective is to investigate whether PPI use by hemato-oncological patients receiving chemotherapy raises the risk of febrile neutropenia. Methods : This is a retrospective database study of patients under hemato-oncological follow up between January 2007 and December 2015, treated with different chemotherapy regimens. Comparative analysis assessed frequencies and types of febrile neutropenia among patients with or without PPI treatment. Multivariate analyses were performed adjusting for age, sub-type of malignancy and specific PPI administered. Results : 247 patients were included, 18–91 years of age (mean 61.6 ± 16), 120 (48.58%) female; amongst 66 (26%) how were hospitalized for febrile neutropenia, 50 (75.8%) received PPIs. Multivariate analysis found three risk factors associated with the development of febrile neutropenia in hematological patients: age, diffuse large B-cell lymphoma and treatment with PPIs. Conclusion : A statistically significant association was demonstrated between PPI treatment and the development of febrile neutropenia among hemato-oncological patients. The clinical implications necessitate further caution in administering PPIs to patients with hematological malignancy receiving chemotherapy.